Thyrotropin-releasing hormone can relieve cancer-related fatigue: Hypothesis and preliminary observations

Journal of International Medical Research

Volumn 37, Issue 4, 2009, Pages 1152-1157

  Kamath, Jayesh ^a   Yarbrough, G G ^b   Prange Jr , A J ^c   Winokur, A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b TRH Therapeutics LLC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cancer related fatigue; Homeostasis; Thyrotropin releasing hormone

Indexed keywords

PLACEBO; PROTIRELIN; HORMONE;

ARTICLE; BREAST CANCER; CANCER FATIGUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HUMAN; HYPERTENSION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANXIETY; BREAST TUMOR; DAILY LIFE ACTIVITY; FATIGUE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ANXIETY; BREAST NEOPLASMS; FATIGUE; FEMALE; HORMONES; HUMANS; INJECTIONS, INTRAVENOUS; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; THYROTROPIN-RELEASING HORMONE; TREATMENT OUTCOME;

EID: 70350497092     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700420     Document Type: Article

References (29)

1. Hofman M, Ryan JL, Figueroa-Moseley CD, et al: Cancer-related fatigue: the scale of the problem. Oncologist 2007; 12(suppl 1): 4-10.
2. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in long-term breast cancer survivors: a longitudinal investigation. Cancer 2006; 106: 751-758.
3. Mock V, Atkinson A, Barsevick A, et al: NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 2000; 14: 151-161.
4. Stone PC, Minton O: Cancer-related fatigue. Eur J Cancer 2008; 44: 1097-1104.
5. Carroll JK, Kohli S, Mustian KM, et al: Pharmacological treatment of cancer-related fatigue. Oncologist 2007; 12(suppl 1): 43-51.
6. Miller AH, Ancoli-Israel S, Bower JE, et al: Neuroendocrine-immune mechanisms of behavioural comorbidities in patients with cancer. J Clin Oncol 2008; 26: 971-982.
7. Payne JK: A neuroendocrine-based regulatory fatigue model. Biol Res Nurs 2004; 6: 141-150.
8. Schubert C, Hong S, Natarajan L, et al: The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007; 21: 413-417.
9. Gary KA, Sevarino KA, Yarbrough GG, et al: The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther 2003; 305: 410-416.
10. Yarbrough GG, Kamath J, Winokur A, et al: Thyrotropin-releasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions. Med Hypotheses 2007; 69: 1249-1256.
11. Kamath J, Yarbrough GG, Prange AJ, et al: The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther 2009; 21: 20-28.
12. Portenoy RK, Itri LM: Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999; 4: 1-10.
13. World Health Organization (WHO): International Classification of Diseases 10th Revision (ICD-10). Geneva: WHO, 1997 (updates to 2008) (available at http://www.who.int/classifications/icd/en).
14. Van Belle S, Paridaens R, Evers G, et al: Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer 2005; 13: 246-254.
15. Smets EM, Garssen B, Bonke B, et al: The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosomat Res 1995; 39: 315-325.
16. Enright PL: The six-minute walk test. Respir Care 2003; 48: 783-785.
17. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
18. Parrott AC, Hindmarch I: The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigation - a review. Psychopharmacology 1980; 71: 173-179.
19. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
20. McNair DM, Lorr M, Droppleman LF: Manual: Profile of Mood States. San Diego: Educational and Industrial Testing Service, 1981.
21. Mellow AM, Sunderland T, Cohen RM, et al: Acute effects of high-dose thyrotropin-releasing hormone infusions in Alzheimer's disease. Psychopharmacology 1989; 98: 403-407.
22. Markes M, Brockow T, Resch KL: Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2006; 18: CD005001.
23. Mar Fan HG, Clemons M, Xu W, et al: A randomized, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008; 16: 577-583.
24. Bruera E, Valero V, Driver L, et al: Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24: 2073-2078. (Pubitemid 46622117)
25. Butler JM Jr, Case LD, Atkins J, et al: A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d- threomethylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007; 69: 1496-1501. (Pubitemid 350116415)
26. Roscoe JA, Morrow GR, Hickok JT, et al: Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005; 89: 243-249. (Pubitemid 43293071)
27. Bruera E, El Osta B, Valero V, et al: Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2007; 25: 3475-3481. (Pubitemid 47310886)
28. Itil TM, Patterson CD, Polvan N, et al: Clinical and CNS effects of oral and I.V. thyrotropin-releasing hormone in depressed patients. Dis Nerv Syst 1975; 36: 529-536.
29. Szuba MP, Amsterdam JD, Fernando III AT, et al: Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol 2005; 25: 325-330.